Biotechnology company Novavax is developing booster shots to help its Covid-19 vaccine protect against newly emerging variants of the coronavirus.
On Thursday, the company announced its vaccine, known as NVX-CoV2373, was found to have an efficacy of 89.3% in a Phase 3 clinical trial conducted in the UK and the vaccine appeared to demonstrate clinical efficacy against some variants of the coronavirus.
Meanwhile, the announcement also noted:
"Novavax initiated development of new constructs against the emerging strains in early January and expects to select ideal candidates for a booster and/or combination bivalent vaccine for the new strains in the coming days. The company plans to initiate clinical testing of these new vaccines in the second quarter of this year."